GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (HKSE:01349) » Definitions » Debt-to-Equity

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Equity?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$0.0 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$10.7 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was HK$2,563.6 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 0.24. The lowest was 0.00. And the median was 0.07.

HKSE:01349's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.29
* Ranked among companies with meaningful Debt-to-Equity only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Equity Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.01 0.01 0.06 0.01

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.05 0.05 0.01 -

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity falls into.



Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (HKSE:01349) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Business Description

Traded in Other Exchanges
Address
No. 308, Cai Lun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Headlines

No Headlines